Dustin S Sjuts Revance Therapeutics, Inc. (RVNC) insider trading activity

Dustin S Sjuts is President of Revance Therapeutics, Inc.. Currently has a direct ownership of 167,550 shares of RVNC, which is worth approximately $430,603. The most recent transaction as insider was on Mar 18, 2024, when has been sold 9,211 shares (Common Stock) at a price of $5.04 per share, resulting in proceeds of $46,423. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 168K

0% 3M change

3.38% 12M change

Total Value Held $430,603

Dustin S Sjuts Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 18 2024	SELL Open market or private sale	$46,423 $5.04 p/Share	9,211 Reduced 5.21%	167,550 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$15,725 $5.3 p/Share	2,967 Reduced 1.65%	176,761 Common Stock
Feb 29 2024	BUY Grant, award, or other acquisition	-	22,110 Added 10.95%	179,728 Common Stock
Dec 31 2023	BUY Grant, award, or other acquisition	$1,972 $7.47 p/Share	264 Added 0.17%	157,618 Common Stock
Dec 15 2023	SELL Payment of exercise price or tax liability	$38,072 $8.08 p/Share	4,712 Reduced 2.91%	157,354 Common Stock
Aug 11 2023	SELL Payment of exercise price or tax liability	$168,317 $18.91 p/Share	8,901 Reduced 5.21%	162,066 Common Stock
Aug 11 2023	BUY Grant, award, or other acquisition	-	22,620 Added 11.68%	170,967 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$15,610 $15.61 p/Share	1,000 Added 0.67%	148,347 Common Stock
Jun 09 2023	SELL Open market or private sale	$154,100 $30.82 p/Share	5,000 Reduced 3.28%	147,347 Common Stock
May 15 2023	SELL Open market or private sale	$726,068 $34.55 p/Share	21,015 Reduced 12.12%	152,347 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$90,938 $30.65 p/Share	2,967 Reduced 2.39%	120,967 Common Stock
Mar 09 2023	SELL Open market or private sale	$679,437 $31.59 p/Share	21,508 Reduced 14.79%	123,934 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$91,858 $33.21 p/Share	2,766 Reduced 2.89%	93,046 Common Stock
Dec 31 2022	BUY Grant, award, or other acquisition	$7,368 $12.18 p/Share	605 Added 0.63%	95,812 Common Stock
Dec 15 2022	SELL Payment of exercise price or tax liability	$62,694 $21.5 p/Share	2,916 Reduced 2.97%	95,207 Common Stock
Sep 22 2022	BUY Grant, award, or other acquisition	-	52,396 Added 26.48%	145,442 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$11,750 $11.75 p/Share	1,000 Added 1.01%	98,123 Common Stock
Mar 15 2022	SELL Payment of exercise price or tax liability	$28,975 $15.79 p/Share	1,835 Reduced 1.85%	97,123 Common Stock
Feb 15 2022	SELL Payment of exercise price or tax liability	$32,427 $13.35 p/Share	2,429 Reduced 2.4%	98,958 Common Stock
Feb 02 2022	BUY Grant, award, or other acquisition	-	52,395 Added 23.21%	173,362 Common Stock
Dec 15 2021	SELL Payment of exercise price or tax liability	$8,167 $15.92 p/Share	513 Reduced 0.5%	101,387 Common Stock
Nov 09 2021	BUY Grant, award, or other acquisition	-	35,920 Added 26.06%	101,900 Common Stock
Jun 30 2021	BUY Other acquisition or disposition	$21,247 $24.09 p/Share	882 Added 1.32%	65,980 Common Stock
Apr 15 2021	SELL Payment of exercise price or tax liability	$11,574 $28.16 p/Share	411 Reduced 0.63%	65,098 Common Stock
Feb 15 2021	SELL Payment of exercise price or tax liability	$69,818 $28.97 p/Share	2,410 Reduced 3.55%	65,509 Common Stock

DSS

Dustin S Sjuts

President

Nashville, TN

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVNC shares.

Notify only if

Value

Insider Trading

Get notified when an Revance Therapeutics, Inc. insider buys or sells RVNC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Revance Therapeutics, Inc.

Track Activities on RVNC

Account